AG
Therapeutic Areas
Celularity Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CYCART-19 (CYNK-101) | Gastric, Gastroesophageal Junction Cancer | Phase 1 |
| CYNK-001 | Acute Myeloid Leukemia (AML), Multiple Myeloma | Phase 1 |
| CYNK-GDT | Glioblastoma Multiforme (GBM) | Preclinical |
| MLASC Platform | Degenerative Diseases (e.g., Osteoarthritis) | Preclinical |
| Biovance® | Diabetic Foot Ulcers, Surgical Reconstruction | Commercial |
| Interfyl® | Musculoskeletal Soft Tissue Repair | Commercial |
| Biovance® 3L | Complex Wounds | Commercial |
Leadership Team at Celularity
RJ
Robert J. Hariri
Chairperson, Founder, and CEO
SB
Stephen Brigido
President, Degenerative Diseases
JH
John Haines
Global Manager and Chief Administrative Officer
SK
Sharmila Koppisetti
Clinical Development Immunology & Drug Safety
CP
Carmine Palummo
Corporate Operations
TW
Tim Wilk
Technical Operations
PD
Peter Diamandis
Director
GS
Geoffrey Shiu Fei Ling
Director
DP
Diane Parks
Director
VL
Vincent LeVien
Director